News

GlobalData on MSN10h
AstraZeneca, Daiichi’s Enhertu shows pCR rate improvement in breast cancer trial
The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, ...
PMLive12h
AstraZeneca/Daiichi Sankyo share positive phase 3 results for Enhertu in early breast cancer
AstraZeneca (AZ) and Daiichi Sankyo have shared positive results from a late-stage study of their HER2-directed antibody drug ...
MedPage Today on MSN23h
Afatinib Improved PFS in Lung Cancer With Uncommon Mutations
Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...
pharmaphorum19h
AstraZeneca improves diabetes pen to maintain its market share
AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).
Indiatimes19h
AstraZeneca Pharma India Share Price
AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 20,466.25 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...